Impact of Amlitelimab (An Anti-OX40 Ligand Antibody) on Maintenance of Itch Response in Atopic Dermatitis: Results From the 52-Week STREAM-AD Phase 2b Study. J of Skin 2025, 9 (6), s604. https://doi.org/10.25251/2ddr5090.